Turing Pharmaceuticals named Craig Rothenberg the company’s chief communications officer. The drugmaker was founded in February.

Rothenberg hails from Johnson & Johnson, where he spent 20 years in a communications capacity, most recently serving as vice president and senior communications leader.

Turing currently has one approved product, Vecamyl, a treatment for managing moderately severe to severe essential hypertension. Turing is also developing a formulation of ketamine for a number of psychiatric indications.